BRPI0509459A - sistemas de distribuição de droga intraocular com liberação sustentada contendo retinóide e métodos de fabricação relacionados - Google Patents

sistemas de distribuição de droga intraocular com liberação sustentada contendo retinóide e métodos de fabricação relacionados

Info

Publication number
BRPI0509459A
BRPI0509459A BRPI0509459-3A BRPI0509459A BRPI0509459A BR PI0509459 A BRPI0509459 A BR PI0509459A BR PI0509459 A BRPI0509459 A BR PI0509459A BR PI0509459 A BRPI0509459 A BR PI0509459A
Authority
BR
Brazil
Prior art keywords
retinoid
manufacturing methods
related manufacturing
drug delivery
sustained release
Prior art date
Application number
BRPI0509459-3A
Other languages
English (en)
Inventor
Patrick M Hughes
Orest Olejnik
Glenn T Huang
Joan-En Chang-Lin
Thierry Nivaggioli
Michele Boix
Christian Sarrazin
Jane Guo Shiah
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0509459A publication Critical patent/BRPI0509459A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

SISTEMAS DE DISTRIBUIçãO DE DROGA INTRA-OCULAR COM LIBERAçãO SUSTENTADA CONTENDO RETINóIDE E MéTODOS DE FABRICAçãO RELACIONADOS". A presente invenção refere-se a implantes intra-oculares bio-compatíveis incluem um componente retinóide e um polímero biodegradável que é eficaz para facilitar a liberação do componente retinóide nos olhos durante um período de tempo prolongado. Os agentes terapêuticos dos implantes podem estar associados a uma matriz polimérica biodegradável, tal como uma matriz que é substancialmente isenta de um álcool polivinílico. Os implantes podem ser colocados nos olhos para tratar ou reduzir a ocorrência de uma ou mais condições oculares, tal como lesão retinal, incluindo glaucoma e vítreo-retinopatia proliferativa.
BRPI0509459-3A 2004-04-30 2005-04-29 sistemas de distribuição de droga intraocular com liberação sustentada contendo retinóide e métodos de fabricação relacionados BRPI0509459A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56733904P 2004-04-30 2004-04-30
US62992804P 2004-11-22 2004-11-22
PCT/US2005/015018 WO2005107707A1 (en) 2004-04-30 2005-04-29 Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
US11/119,024 US20050271705A1 (en) 2004-04-30 2005-04-29 Retinoid-containing sustained release intraocular drug delivery system and related methods

Publications (1)

Publication Number Publication Date
BRPI0509459A true BRPI0509459A (pt) 2007-09-04

Family

ID=34972221

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509459-3A BRPI0509459A (pt) 2004-04-30 2005-04-29 sistemas de distribuição de droga intraocular com liberação sustentada contendo retinóide e métodos de fabricação relacionados

Country Status (9)

Country Link
US (3) US20050271705A1 (pt)
EP (1) EP1765284A1 (pt)
JP (1) JP2007535563A (pt)
AR (1) AR056254A1 (pt)
AU (1) AU2005240078A1 (pt)
BR (1) BRPI0509459A (pt)
CA (1) CA2565285A1 (pt)
TW (1) TW200538163A (pt)
WO (1) WO2005107707A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US9421175B2 (en) 2004-03-17 2016-08-23 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7998717B2 (en) 2005-12-02 2011-08-16 Pacific Biosciences Of California, Inc. Mitigation of photodamage in analytical reactions
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8492334B2 (en) * 2007-06-21 2013-07-23 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
CA2723588A1 (en) 2008-05-12 2009-11-19 University Of Utah Research Foundation Intraocular drug delivery device and associated uses
US20110206773A1 (en) * 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
EP2296621A1 (en) * 2008-05-20 2011-03-23 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
CN102395401B (zh) * 2009-02-12 2015-08-19 因赛普特有限责任公司 经由水凝胶塞的药物递送
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
US8834847B2 (en) 2010-08-12 2014-09-16 Pacific Biosciences Of California, Inc. Photodamage mitigation compounds and systems
CA2809374C (en) 2010-09-01 2021-02-23 Thomas Jefferson University A composition comprising a retinoic acid receptor gamma agonist and its use for muscle repair and regeneration
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
EP2714016A1 (en) * 2011-06-03 2014-04-09 Allergan, Inc. Targeted delivery of retinoid compounds to the sebaceous glands
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US10226536B2 (en) 2011-11-28 2019-03-12 Case Western Reserve University Polysaccharide therapeutic conjugates
NZ708756A (en) * 2012-11-08 2019-07-26 Univ Yamaguchi Therapeutic agent for keratoconjunctive disorders
WO2014085494A1 (en) * 2012-11-28 2014-06-05 Aphios Corporation Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
US10123988B2 (en) 2013-03-15 2018-11-13 Allergan, Inc. Compositions including encapsulated isotretinoin and methods for use thereof
BR112015029114B1 (pt) 2013-05-22 2020-11-24 Yamaguchi University composição
US20150209342A1 (en) 2014-01-28 2015-07-30 Allergan, Inc. Topical retinoid formulations, processes for making and methods of use
JP6655610B2 (ja) 2014-05-29 2020-02-26 グローコス コーポレーション 制御された薬物送達機能を備えるインプラント及びそれを使用する方法
US10471118B2 (en) 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
WO2015187840A2 (en) * 2014-06-03 2015-12-10 Duke University Methods and formulations for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
IL295440A (en) 2016-06-08 2022-10-01 Clementia Pharmaceuticals Inc Methods for the treatment of heterotopic aggravation
JP7018957B2 (ja) 2016-11-16 2022-02-14 クレメンティア ファーマシューティカルズ インコーポレイテッド 多発性骨軟骨腫（ｍｏ）を処置するための方法
CN111358766A (zh) * 2020-04-13 2020-07-03 青岛大学 一种包载他扎罗汀的plga纳米粒及其制备方法、用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
WO1999007418A2 (en) * 1997-08-11 1999-02-18 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
JP2002003406A (ja) * 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
DE60128261T3 (de) * 2000-12-21 2016-06-30 Alrise Biosystems Gmbh Verfahren umfassend einen induzierten phasenübergang zur herstellung von hydrophobe wirkstoffe enthaltenden mikropartikeln
WO2003082081A2 (en) * 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Use of rom production and release inhibitors to treat and prevent intraocular damage
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing

Also Published As

Publication number Publication date
AR056254A1 (es) 2007-10-03
CA2565285A1 (en) 2005-11-17
US20110076318A1 (en) 2011-03-31
US20090163550A1 (en) 2009-06-25
AU2005240078A1 (en) 2005-11-17
TW200538163A (en) 2005-12-01
US20050271705A1 (en) 2005-12-08
EP1765284A1 (en) 2007-03-28
WO2005107707A1 (en) 2005-11-17
JP2007535563A (ja) 2007-12-06

Similar Documents

Publication Publication Date Title
BRPI0509459A (pt) sistemas de distribuição de droga intraocular com liberação sustentada contendo retinóide e métodos de fabricação relacionados
BRPI0510472A (pt) implantes intra-oculares de liberação prolongada antiexcitotóxicos e métodos relacionados
BRPI0510471A (pt) derivado de estradiol ou um derivado de estratopona contendo implante intra-ocular de liberação constante bem como métodos relacionados de fabricação
BRPI0510485A (pt) implantes inibidores de tirosina cinase intravìtreos biodegradáveis
Lee et al. Biodegradable implants for sustained drug release in the eye
BRPI0509461A (pt) implantes intravìtreos compreendendo microesferas que encapsulam um inibidor de tirosina cinase e um polìmero biodegradável
MX2010012022A (es) Suministro de liberacion sostenida de agentes activos para tratar glaucoma e hipertension ocular.
BRPI1007318A2 (pt) distribuição com liberação sustentada de um ou mais agentes.
BRPI0513243B8 (pt) composições oftálmicas e respectivos usos
BR112012026535A2 (pt) redução de pressão intraocular com implantes de bimatoprost intracameral
WO2014165308A3 (en) Microsphere drug delivery system for sustained intraocular release
JP2010507686A5 (pt)
JP2010533225A5 (pt)
HUP0001818A2 (hu) A szem első kamrájában alkalmazható szabályzott felszabadulású gyógyszerhatóanyagok
JP2007535539A5 (pt)
TW200605853A (en) Steroid-containing sustained release intraocular implants and related methods
BRPI0607606A2 (pt) formulações lìquidas para tratamento de doenças ou condições
BR0302584A (pt) Combinação de brimonidina e timolol para uso oftálmico tópico
AR064078A1 (es) Sistema de administracion de farmacos intraocular inyectable biocompatible, su uso para preparar un medicamento y proceso para su preparacion
EP2427174A4 (en) HEMMER OF THE MTOR SIGNAL PATH FOR THE TREATMENT OF EYE TROUBLE
RU2011106329A (ru) Глазное устройство, обладающее способностью доставки терапевтического средства и способ получения такового
Tao et al. Role of corneal epithelium in riboflavin/ultraviolet-A mediated corneal cross-linking treatment in rabbit eyes
BR112013018739A2 (pt) sistema de distribuição de medicamento ocular
Srinivasan Topical ketorolac tromethamine 0.5% versus diclofenac sodium 0.1% to inhibit miosis during cataract surgery
Bellucci et al. Comparative efficacy of topical tetracaine solution versus lidocaine gel in cataract surgery

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.